# DocGo Inc.: overview DCGO · Nasdaq · CIK 1822359 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/dcgo.md) · [Financials](/companies/dcgo/financials.md) · [Filings](/companies/dcgo/filings.md) · [Insiders](/companies/dcgo/insiders.md) Latest reported revenue: [$73.4m](/filings/0001628280-26-057394.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 17, 2026 (XBRL us-gaap:Revenues, accession 0001628280-26-057394). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [139](/filings/0001628280-25-051102.md) | [121 d](/filings/0001628280-26-018214.md) | [96.0](/filings/0001628280-26-033563.md) | [80.4](/filings/0001628280-26-057394.md) | [70.8](/filings/0001628280-25-051102.md) | [74.9 d](/filings/0001628280-26-018214.md) | [75.6](/filings/0001628280-26-033563.md) | [73.4](/filings/0001628280-26-057394.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [7.3%](/filings/0001628280-25-051102.md) | [(6.2%) d](/filings/0001628280-26-018214.md) | [(14.6%)](/filings/0001628280-26-033563.md) | [(21.7%)](/filings/0001628280-26-057394.md) | [(59.3%)](/filings/0001628280-25-051102.md) | [(139.6%) d](/filings/0001628280-26-018214.md) | [(24.8%)](/filings/0001628280-26-033563.md) | [(24.4%)](/filings/0001628280-26-057394.md) | | Net margin | % | [4.0%](/filings/0001628280-25-051102.md) | [(2.7%) d](/filings/0001628280-26-018214.md) | [(9.8%)](/filings/0001628280-26-057394.md) | [(13.9%)](/filings/0001628280-26-057394.md) | [(39.2%)](/filings/0001628280-25-051102.md) | [(178.9%) d](/filings/0001628280-26-018214.md) | [(19.5%)](/filings/0001628280-26-057394.md) | [(21.5%)](/filings/0001628280-26-057394.md) | | Diluted EPS | $ per share | [0.05](/filings/0001628280-25-051102.md) | not reported | [(0.09)](/filings/0001628280-26-033563.md) | [(0.11)](/filings/0001628280-26-057394.md) | [(0.28)](/filings/0001628280-25-051102.md) | not reported | [(0.15)](/filings/0001628280-26-033563.md) | [(0.16)](/filings/0001628280-26-057394.md) | | Free cash flow | $m | [26.9 d](/filings/0001628280-25-051102.md) | [12.0 d](/filings/0001628280-26-018214.md) | [8.2](/filings/0001628280-26-033563.md) | [32.9 d](/filings/0001628280-26-057394.md) | [0.8 d](/filings/0001628280-25-051102.md) | [(12.0) d](/filings/0001628280-26-018214.md) | [(5.1)](/filings/0001628280-26-033563.md) | [(9.6) d](/filings/0001628280-26-057394.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [319](/filings/0001822359-24-000016.md) | [441](/filings/0001822359-25-000018.md) | [624](/filings/0001628280-26-018214.md) | [617](/filings/0001628280-26-018214.md) | [322](/filings/0001628280-26-018214.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [4.8%](/filings/0001822359-24-000016.md) | [5.0%](/filings/0001822359-25-000018.md) | [2.4%](/filings/0001628280-26-018214.md) | [4.7%](/filings/0001628280-26-018214.md) | [(55.3%)](/filings/0001628280-26-018214.md) | | Net margin | % | [7.4%](/filings/0001213900-23-019936.md) | [7.9%](/filings/0001213900-23-019936.md) | [1.1%](/filings/0001628280-26-018214.md) | [3.2%](/filings/0001628280-26-018214.md) | [(56.6%)](/filings/0001628280-26-018214.md) | | Diluted EPS | $ per share | [0.25](/filings/0001822359-24-000016.md) | [0.34](/filings/0001822359-25-000018.md) | [0.06](/filings/0001628280-26-018214.md) | [0.18](/filings/0001628280-26-018214.md) | [(1.84)](/filings/0001628280-26-018214.md) | | Free cash flow | $m | [(6.8)](/filings/0001822359-24-000016.md) | [25.7](/filings/0001822359-25-000018.md) | [(71.8)](/filings/0001628280-26-018214.md) | [66.5](/filings/0001628280-26-018214.md) | [29.9](/filings/0001628280-26-018214.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/dcgo/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.9m | 3,728,207 | | Added +45,639 | | [P.A.W. CAPITAL CORP](/funds/949853.md) | 2026-06-30 | $1.8m | 3,505,000 | | Added +505,000 | | [Knott David M Jr](/funds/1892770.md) | 2026-06-30 | $1.4m | 2,670,850 | | Unchanged | | [Peapod Lane Capital LLC](/funds/2050979.md) | 2026-06-30 | $1.3m | 2,500,118 | | Added +1,370,924 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $1.2m | 2,353,610 | | Reduced −146,390 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $1.2m | 2,254,370 | | Added +744,009 | | [S SQUARED TECHNOLOGY, LLC](/funds/1322924.md) | 2026-06-30 | $1.1m | 2,055,271 | | Unchanged | | [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $882.0k | 1,708,962 | | Added +973,704 | | [MOORE CAPITAL MANAGEMENT, LP](/funds/1448574.md) | 2026-06-30 | $756.1k | 1,465,000 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $750.4k | 1,454,063 | | Reduced −4,911,965 | ## Recent filings [All 411 filings](/companies/dcgo/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-05 | 10:32 ET | [8-K](/filings/0001628280-26-064740.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 8.01 Other events | 0001628280-26-064740 | | 2026-08-17 | 20:35 ET | [10-Q](/filings/0001628280-26-057394.md) | Quarterly report, period 2026-06-30 | 0001628280-26-057394 | | 2026-08-17 | 20:24 ET | [8-K](/filings/0001628280-26-057387.md) | 1.01 Entry into a material agreement; 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-057387 | | 2026-07-31 | 20:06 ET | [8-K](/filings/0001628280-26-051396.md) | 3.01 Delisting notice | 0001628280-26-051396 | | 2026-07-02 | 20:17 ET | [8-K](/filings/0001628280-26-046919.md) | 7.01 Regulation FD disclosure | 0001628280-26-046919 | | 2026-06-18 | 21:06 ET | [8-K](/filings/0001628280-26-044414.md) | 5.07 Shareholder vote results | 0001628280-26-044414 | | 2026-05-11 | 20:32 ET | [10-Q](/filings/0001628280-26-033563.md) | Quarterly report, period 2026-03-31 | 0001628280-26-033563 | | 2026-05-11 | 20:09 ET | [8-K](/filings/0001822359-26-000020.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001822359-26-000020 | | 2026-04-22 | 20:06 ET | [DEF 14A](/filings/0001213900-26-046600.md) | Proxy statement, period 2026-06-16 | 0001213900-26-046600 | | 2026-04-22 | 01:32 ET | [8-K](/filings/0001822359-26-000017.md) | 5.02 Departure or appointment of officers or directors | 0001822359-26-000017 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-018214.md), filed Mar 16, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/405a7a89-6fb7-4768-9feb-194a97731844) ## About the filer - CIK: 1822359 - Tickers: DCGO - Exchange: Nasdaq - SIC code: 8000 Services-Health Services - State of incorporation: DE - Filer category: Accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.